Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM et al.
Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials.
JAMA 2005,294,1664-1670 Shah
Bottom line: it doesn’t kill people, and it doesn’t help either…..
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al.
Early goal-directed therapy in the treatment of severe sepsis and septic shock.
NEJM 2001,345,1368-1377 Rivers
Goal-directed therapy does work, if you hit them soon enough…………
Jones AE, Brown MD, Trzeciak S, Shapiro NI, Garrett JS et al.; Emergency Medicine Shock Research Network
The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: a meta-analysis.
CCM 2008,36,2734-2739 Jones
Like the Daddy of goal-directed therapy said before ( CCM 2002,30,1686-1692 Kern ): it only works if you hit ’em early!
Leone M, Martin C.
Vasopressor use in septic shock: an update.
Current opinion in Anaes 2008,21,141-147 Leone
So we still don’t know which inotrope to use….
Póvoa PR, Carneiro AH, Ribeiro OS, Pereira AC; on behalf of the Portuguese Community-Acquired Sepsis Study Group.
Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study).
CCM 2009,37,410-416 Póvoa
… but maybe it shouldn’t be noradrenaline…?
Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC et al.: the VASST Investigators
Vasopressin versus norepinephrine infusion in patients with septic shock.
NEJM 2008,358,877-887 Russell
It’s here, it’s VASST, it’s … a bit inconclusive, really
Pearse RM, Belsey JD, Cole JN, Bennett ED.
Effect of dopexamine infusion on mortality following major surgery: individual patient data meta-regression analysis of published clinical trials.
Critical Care Medicine 2008; 36: 1323-9.
Dopexamine: the dark horse of inotropes!
Archan S, Toller W.
Levosimendan: current status and future prospects.
Current opinion in Anaes 2008,21,78-84 Archan
Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, et al. (EVEREST Investigators).
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Journal of the American Medical Association 2007; 297: 1332-43
Encouraging – but what about the real outcomes………….?
PubMed Abstract JAMA Full Text
Nesiritide – not verified.
New England Journal of Medicine 2005; 353: 113-6.
The forthcoming ETNA trial could determine whether Nesiritide makes it into Europe – or will ASCEND get there first?.
PubMed (no abstract) NEJM Full Text